This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Efinopegdutide
Clinical data
Other names
MK-6024
Legal status
Legal status
Investigational
Identifiers
CAS Number
2055640-93-0
UNII
DR6P1M58PO
Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It was also developed for type 2 diabetes and obesity but these indications were discontinued.[1][2][3][4]
^Romero-Gómez, Manuel; Lawitz, Eric; Shankar, R. Ravi; Chaudhri, Eirum; Liu, Jie; Lam, Raymond L.H.; Kaufman, Keith D.; Engel, Samuel S.; Bruzone, Santiago Oscar; Coronel, Maria Jimena; Gruz, Fernando M.; MacKinnon, Ignacio; George, Jacob; Muller, Kate; Lee, Samuel S. (2023-06-22). "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease". Journal of Hepatology. 79 (4): 888–897. doi:10.1016/j.jhep.2023.05.013. hdl:10261/349752. ISSN 0168-8278.
^Novikoff, Aaron; Müller, Timo D. (July 2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi:10.1016/j.peptides.2023.171003. PMC 10265134. PMID 36997003.
^Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. PMID 34176426. S2CID 235661514.
Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It...